GENE ONLINE|News &
Opinion
Blog

Breast Cancer
Menarini’s Oral SERD Gains First-Ever FDA Approval for Breast Cancer
2023-01-30
Action Date Set for Gilead Sciences’ HR+/HER2- breast cancer sBLA
2022-10-11
Roche’s Newly Approved Companion Diagnostic May Open Treatment Options for HER2-low Patients
2022-10-06
AstraZeneca and Merck’s HER2-negative Breast Cancer Treatment Wins Yet Another Approval
2022-08-25
Sanofi Abandons SERD Candidate After Second Breast Cancer Clinical Trial Blow
2022-08-18
Gilead Forking Over $280 million to Everest to Regain Rights to Breast Cancer Treatment
2022-08-16
Gilead’s New Chemotherapy for Metastatic Breast Cancer Demonstrates Increase in Overall Survival
2022-08-15
First Targeted Therapy for HER2-Low Breast Cancer Approved by FDA
2022-08-05
Amazon, Fred Hutchinson Begin Human Trial for Cancer Vaccine
2022-07-14
Organon Licenses Biosimilars From Shanghai’s Henlius For $103 Million
2022-06-14
Everest Medicines Secures Breast Cancer Drug Approval in China
2022-06-13
ASCO 2022: AstraZeneca, Pfizer, Novartis Share Key Data on Breast Cancer Therapeutics
2022-06-07
Everest and Gilead Announce Positive Phase 3 Results of Breast Cancer Drug
2022-06-06
EU Expands Merck’s Keytruda Use on Breast Cancer
2022-05-25
REVEAL GENOMICS and Dana-Farber Cancer Institute Team Up to Research Breast Cancer
2022-04-29
1 2 3 4
LATEST
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
First-Ever Insect Brain Neuron Map Completed
2023-03-21
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
2023-03-19
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
2023-03-19
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
Scroll to Top